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1. Introduction 
1.1 How define a SIM? 
According to FDA guideline (Guidance for Industry, Analytical Procedures and Methods 
Validation, FDA, 2000), a Stability Indicating Method (SIM) is defined as a validated 
analytical procedure that accurate and precisely measure active ingredients (drug substance 
or drug product) free from process impurities, excipients and degradation products. The 
FDA recommends that all assay procedures for stability should be stability indicating. The 
main objective of a stability indicating method is to monitor results during stability studies 
in order to guarantee safety, efficacy and quality. It represents also a powerful tool when 
investigating out-of-trend (OOT) (Swartz et al., 2004) or out-of-specification (OOS) results 
(CDER, 2006) in quality control processes. 
1.2 How develop a SIM? 
There are basically 3 steps necessary for developing a SIM:  
1.2.1 Step 1: generation of degraded samples for testing selectivity of the method 
Here lies one of the main concerns related to a development of a SIM, since the available 
guidance documents do not state the extent to which stress tests should be carried out – 
that is, how much stress should be applied or how much degradation should be aimed 
for.  
In fact, there is not a “gold rule” that attends this issue and therefore, it is important to keep 
in mind that experimental conditions of stress tests, should be realistic and lead to 
“purposeful degradation” (Ngwa, G., 2010).  
Stress tests should generate representative samples to assess drug substance and drug product 
stability, provide information about possible degradation pathway and demonstrate the 
stability indicating power of the analytical procedures applied.  
1.2.1.1 Determination of Limit of Quantification (LoQ) 
In close relation to the determination of the amount of degradation is the evaluation of Limit 
of Detection (LoD) and Limit of Quantification (LoQ) of the method. These limits should be 
closely related to the Reporting, Identification and Qualification of degradation products, as 
stated in ICH Q3B (R2) (EMEA, 2006). These thresholds are determined either as percentage 
of drug substance or total daily intake (TDI) of degradation product. 
www.intechopen.com
 
Quality Control of Herbal Medicines and Related Areas 
 
26 
The analytical methods are usually expected to be validated for the ability to quantify potential 
degradation products and drug impurities with a LoD and LoQ at least as sensitive as the 
ICH threshold (see Figure 1).  
 
 
Fig. 1. ICH thresholds for degradation products in New Drug Application (ICH Q3B) 
The identification threshold (IT) varies from 0.1 to 1.0% of the labeled amount of active 
ingredient in the dosage form, or from 5 μg to 2 mg TDI, depending on the maximum daily 
dosage in the product´s professional labeling. The identification threshold may be lowered 
for degradation products that may be exceptionally toxic.  
The Reporting Threshold (RT) is either 0.1% or 0.05% depending on the maxim daily 
dosage. For very low dose drug products, where this type of sensitivity is not attainable, 
even after exhaustive tentative, justification may be provided describing the failed reports. 
Process-related drug substance impurities that are also degradation products should have 
the same limits as for ICH Q3B.  
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Ideally, the same analytical methodology should be used for Quality Control and Stability 
Studies. The determination of Out-of-Specification or Out-of-Trend results should be more 
reliable, when using a SIM, since LoD and LoQ used allows detection of impurities and/or 
degradation products adequately. In the situation in which a new peak arises during 
stability study and one may expect that it should not exist and hence it would constitute a 
type of OOT, the use of a well studied and well determined LoQ in a SIM, will help the 
applicator to decide if additional action are needed to investigate a new substance or a OOT. 
It should be mentioned that these thresholds are established for new drug products or New 
Drug Application (NDA). For Abbreviated New Drug Application (ANDA) or generic drugs, 
there are not specific regulations about this topic and even less, the companies dealing with 
these products, have background information as those obtained in the development of 
NDA. Such application is expected to contain a “full description of the drug substance 
including its physical and chemical characteristics and stability as well; such specifications 
and analytical methods are necessary to assure the identity, strength, quality, purity and 
bioavailability of drug product and stability data with proposed expiration date”. As already 
cited, for ANDA, there are not specific regulations and the same ICH recommendation has 
been used. However, precisely because of the lack of information derived from the new 
drug development, the complexity and responsibility in developing/validating a SIM for an 
ANDA is high. 
Information like aqueous solubility, pH versus solubility profile, excipients compatibility 
studies, etc, all information that enable fully assume the knowledge of the product ,will help 
to ensure that best (more appropriate) condition were chosen for developing a SIM, like 
those related to the forced degradation design. 
1.2.1.2 Overstressing/Understressing 
Care should be taken in order to avoid overstressing or understressing samples, with may 
lead to non representative or non-purposeful degradation. So, the use of a properly designed 
and executed forced degradation study will generate representative samples that will help 
to ensure that resulting method reflects adequately long-term stability (EMEA, 2003).  
About the forced degradation (or stress test, both terms will be used in the text) design, it is 
recommended (Klick S., et al, 2005) to include alkaline and acidic hydrolysis, photolysis, 
oxidation, humidity and temperature stress. An compilation of data from literature (Klick S., 
et al, 2005; Alsante et al. 2007, Reynolds, et al. 2002, Reynolds, D.W, 2004; Kats M., 2005; 
Reynolds, D.W, 2002) is shown at Table 1 and compiles the more often used conditions to 
perform forced degradation studies. 
These conditions can be used as a starting point in the development of a SIM. Changing 
conditions to harsher or softer levels, can be applied, when too little or too much 
degradation are obtained. For example, in cases in which too little degradation was obtained 
in the hydrolyses stress, it is recommended to increase concentrations to 1 Mol L-1 or higher; 
for oxidation stress, increase peroxide concentration to 10% or 20% (v/v) and/or time of 
reaction, as well as temperature. If co-solvents are necessary to increase solubility, it is 
recommended the use of acetonitrile that does not work as a sensitizer in photostability 
stress. Data needs to be evaluated as unusual degradants may form with co-solvents. If even 
not all conditions may cause degradation, document efforts and severity of conditions and 
should be include in final report. 
By the other side, if too much degradation is detected, the severity of conditions may be 
decreased, by diluting acid/bases, neutralizing, reducing exposure time. 
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Solid State 
Stress Condition Period of time 
Heat 60° C Up to 1 month 
Humidity 75% RH Up to 1 month 
Photostability 
3 mm (powder) 
Exposed and non-exposed 
samples (“control”) 
Follow ICH requirements 
(Q1B) 
Solution State 
Stress Condition Period of time 
Acid 0.1 – 1 Mol L-1 HCl Up to weeks and 60° C Hydrolys
is alkaline 0.1 – 1 Mol L-1 NaOH Up to weeks and 60° C 
Oxidation H2O2 3% (v/v) Up to 24 hours 
Photostability 
Exposed and non-exposed 
samples (“control”) 
Follow ICH requirements 
(Q1B) 
Heat 60° C Up to 1 month 
Table 1. “More often” used conditions for forced degradation studies 
Also, need to be clarified, that synthesis impurities when are not also degradation products 
do not need to be described in Stability Studies, but SIM may assure that these impurities do 
not interfere on degradation products determination. 
1.2.1.3 Photostability studies 
Photostability tests should follow ICH requirements (EMEA, 1998) , i.e., should be done in a 
sequential manner, starting with the fully exposed product and proceeding, if necessary to 
the immediate pack and then to the market pack, until studies demonstrate the drug 
product is adequately protected from exposure to light. Besides this, design of forced 
degradation test should consider the previous knowledge of the substance or product being 
tested, since photoreactivity is wavelength dependent and degradation pathways can be 
different for UV and visible ranges (case by case basis). It is recommended to use artificial 
sources of irradiation, like ID65 and specific filters to guarantee the exposure above 320 nm 
(indoor daylight standard). Also, forced degradation may be conducted on quartz glassware 
that does not filter radiation from the light sources and specific filters arrangement. 
It can be found in literature (ICH Q1B) that exposition to an overall irradiation of not less 
than 1.2 million lux.hours and an integrated near ultraviolet energy of not less than 200 W h. 
m-2 may give reasonable degradation for photosensible active ingredients. Tests may only be 
valid when chemical actinometers are exposed simultaneously (preferably) to the samples 
and shows a pattern of degradation. Control samples (samples in the same condition of that 
exposed, except for the irradiation, i.e., protected from the light by aluminum foils for 
example) should also be analyzed, in order to guarantee that the degradation is really only 
due to the light and not to other factors like temperature (irradiation chamber should have 
rigorous temperature control) (Christensen, K. et. al 2000). In some cases, the ANDA holder 
justifies not performing photostability studies for the drug product based on the fact that the 
drug substance did not show photodegradation during forced degradation studies. 
However, this not must be acceptable, since in some cases, excipients or impurities may 
catalyze photodegradation of the main active in the drug product. 
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1.2.2 Step 2: method development (manipulating and evaluating selectivity/specificity) 
Liquid chromatography is the most appropriate technique for developing/validating a SIM. 
The use of diode-array-detector and additionally mass spectrometers, gives best performances 
for people working with SIM development.  
The goal is to manipulate selectivity by changing mobile phase composition, wavelength of 
detection and pH. Related to mobile phase pH, it can be said, that the advances in LC 
column technology have made possible the use of pH as a true selectivity tool for the 
separation of ionizable compounds (Neue, et. al, 1999; Cheng et. al, 2010). Columns 
mechanically strong, with high efficiency and that are operate over an extended pH range, 
should be preferred. Acidic compounds are more retained at low pH; while basic 
compounds are more retained at higher pH (neutral compounds are unaffected). At 
traditionally used pH values (pH 4 - 8), a slight change in pH would result in a significant 
shift in retention.  
Type of chromatography used (e. g. HPLC or GC) and arrangements/detectors (GC/FID, 
GC/MS, LC/DAD or LC/MS) are certainly useful tools. For HPLC, different modes of 
chromatography can be used (normal or reversed phase, ion par or HILIC). Other powerful 
tool is the use of Light Scattering Detector (LSD) coupled to HPLC to monitor compounds 
without light absorption in uv/Vis region. Gas chromatography may only be used when no 
additional thermal degradation of the sample is produced (sample inlet works on high 
temperatures). 
The use of HLPC coupled to diode-array detectors (DAD) in the achievement of peak purity 
usually give reasonable results, mainly related to reliable determination of the main active 
ingredient. It is possible to guarantee no co-elution with degradation peaks and other 
impurities. Indeed, the main feature of DAD detectors is that it is possible to collect spectra 
across a range of wavelengths at each data point collected across a peak, and through 
software manipulations involving multidimensional vector algebra, to compare each of the 
spectra to determine peak purity (Swartz & Krull, 2005; Gilliard & Ritter, 1997). In this 
manner, DAD detectors can distinguish spectral and chromatographic differences not 
readily observable by simple overlay comparisons (Gorenstein et al 1994; Young et al 1994, 
Warren et al 1995). DAD detectors can be limited on occasion the more similar the spectra, 
and the lower the relative absorbance, the more difficult it can be to distinguish co-eluted 
compounds. MS detection overcomes many of these limitations. MS can provide 
unequivocal peak purity information, exact mass, structural and quantitative information 
depending upon the type of instrument used. MS is also a very useful tool to track peaks to 
selectivity manipulations in method development. As disadvantage, MS detectors cannot 
handle non-volatile buffers, which are frequently used as mobile phase in drug analysis. The 
combination of both DAD and MS on a single instrument and software platform provides 
the type of valuable orthogonal information required when evaluating specificity on SIM 
development. 
After determination of peak purity, in fact, the identification of degradation products and 
also mass balance determination usually are more complexes steps of analytical development, 
as in most of cases, commercial reference standards of degradation products are not 
available. 
Calculations using area-percent-normalization (area %) are not precise, since it is necessary 
to take into consideration the response factors (area relative to amount). Degradation 
products may have not the same ultra-violet spectra of that of the parent drug and even if 
the UV spectra are similar, the absorptivity coefficient (Turro 2008) may have different values. 
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1.2.2.1 Case studies 
Case study 1: Consider the analysis of a 100 mg tablet used in medical prescriptions as 3-dose 
per day and coming from a long term stability study (Figure 1). 
 
 
Fig. 1. Representative SIM chromatogram of long-term stability sample 
The quantification of degradation product by %area results in 0.2% area for degradation A 
and 12% area for degradation B, related to the main active. It is confirmed that the 
degradation products are deriving from the main active, as a SIM was used. Information 
about UV spectra of both degradation products and main active are shown in Figure 2. 
 
 
Main active 
  
                            Degradation A                                                          Degradation B 
Fig. 2. Representative uv spectra of degradation products A and B 
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By simple comparison of spectra of main active and degradation A, it can be assumed that 
mass balance would be probably reached, due to high similarity between it; for degradation 
B mass balance may give unsatisfactory results, mainly if wavelength of detection and 
quantification is in the 250-275 nm region of the spectra. Other concern is related to the ICH 
threshold for the degradation products. In this case, the diary dose is 300 mg and 
degradation products A (0.2%) and B (12%) fall within the range of identification and 
qualification, which would means to define toxicity and mutagenicity potential of these two 
degradation products, and ultimately also redesign the drug product.  
Case study 2: 
In this second example (representative chromatogram showed on Figure 3), one may 
consider that when the sample is submitted to light stress the main active degrades to seven 
different products (see Table 2) and besides these seven common degradation more new 
two degradation can be detected in acidic stress (Table 3). 
 
 
Fig. 3. SIM chromatogram of light stressed sample - 48 hours 
Calculation of mass balance by considering % area of degradation product peaks, identified 
by Relative Retention Time (RRT) is also presented in tables 2 and 3. 
 
% peak area 
RRT
λdetector 0.17 0.24 0.55 0.69 0.74 0.81 0.88 0.92 1.22
Sub-
Total
Total 
210 nm 0.2 1.3 nd nd 3.6 0.2 0.1 0.3 0.9 6.6 80.7 
245 nm 0.3 2.4 nd nd 0.5 0.15 <LoQ <LoQ 1.0 4.75 78.9 
360 nm <LoQ <LoQ nd nd <LoQ <LoQ <LoQ 0.17 1.0 1.17 
Main 
Active* 
74.1% 
75.3 
*this value represents % of main active on drug product, determined by external calibration with main 
active analytical standard; nd = non detected 
Table 2. Peak % area degradation products after 48- hours of light stress 
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% peak area 
RRT
λdetector 0.17 0.24 0.55 0.69 0.74 0.81 0.88 0.92 1.22
Sub-
Total
Total 
210 nm 0.3 0.2 0.2 0.2 2.3 1.85 <LQ <LQ <LQ 5.05 80.45 
245 nm <LQ <LQ 0.2 <LQ 0.3 1.4 <LQ <LQ <LQ 1.9 77.3 
360 nm <LQ <LQ <LQ <LQ <LQ <LQ <LQ <LQ <LQ <LQ
Main 
Active* 
75.4% 
<LQ 
*this value represents % of main active on drug product, determined by external calibration with main 
active analytical standard. 
Table 3. Peak % area degradation products after 120-hours of acidic stress 
In the light stress (Table 2), the concentration of the main active after 48 hours is around 
74.1%, and for an acceptable mass balance determination (values in % area or concentration 
around target concentration value), degradation products must account for 25.9% area. As 
can be seen at Figure 4, the UV spectra given from the DAD of these nine degradation 
products, there are significative differences in the profiles, i.e., different absorption 
intensities in different wavelength and this should be an indicative of difficulties on 
reaching satisfactory mass balance using % area. 
When monitoring at 210 nm, mass balance reached 80.7%, since the sum of total % area of 
degradation products reached 6.6% area. 
When doing the same calculation for 245 nm, mass balance was lower, reaching 78.9%  
and even lower at 360 nm, giving 75.3%. Degradation products identified at RRT-0.55  
and RRT-0.69 were not detected at these three wavelengths, but were detected on acidic 
stress (Table 3) sample, when monitoring at 210 nm and 245 nm. Any degradation product 
was detected at 360 nm, in the acidic stress. Usually greater values are obtained in lower 
wavelengths. 
Most frequently giving acceptable mass balance values, but not less complex, is the method 
in which chromatographic peaks of each degradation product is collected and identified (for 
example, by infrared spectroscopy, nuclear magnetic resonance as well as mass 
spectrometry analysis) and then used as analytical standards in a external calibration 
procedure. The method in which, response factor of each degradation product is achieved 
(also experimentally hard and complex), can give acceptable mass balance values. The 
determination of each degradation product is a critical work mainly when ICH thresholds 
are reached. This may trigger additional investigations about the drug product, so it is 
recommended to dedicate all analytical tools and expertise available in this step of method 
development. 
1.2.3 Step 3: Method validation 
Validation is not a efficient way to do method development so efforts should be dedicated  
in Specificity step of the method, working with the stressed samples. The validation 
routine may start with a protocol based on pharmacopeia and/or ICH guidelines (Q2B). For 
assay procedures, that are intended do measure the analyte present in a given sample, 
typical validation items should be considered: Accuracy, Precision (repeatability and 
intermediate precision), Specificity, Detection and Quantitation Limits, Robustness, 
Linearity and Range. 
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Fig. 4. UV-vis spectra of degradation products observed on light stressed samples (b, c, f to j) 
and acidic stressed samples (b to g). 
(b) RRT 0.17 
(c) RRT 0.24active (d) RRT 0.55 
(e) RRT 0.69
(g) RRT 0.81 (h) RRT 0.88 
(i) RRT 0.92 (j) RRT 1.22  
(a) Main active
(f) RRT 0.74 
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2. Conclusion 
Stress tests for developing a stability indicating method should always be designed and 
evaluated with common sense and chemical knowledge, keeping in mind the 
manufacturing process and the nature of the final drug product. The stability profile needs 
do be established for drug product to assure safety, efficacy and quality. The results coming 
from these studies can support formulation and packaging. The know-how coming from 
stress tests are useful to reduce time and money, related to the drug and final product 
development, giving the possibility of forecasting analytical problems.  
A generic approach can be used as a starting point to set up a stress testing study, but a 
case-by-case approach for stress testing is essential to allow flexibility. This is also 
recognized by the regulatory agencies because very detailed instructions about how to 
perform stress testing are not given in the available guidance documents. In first instance, a 
SIM should be applied to quantification of the main active in a precise and accurately, even 
in the presence of interferences (degradation products, impurities, and placebo). In this 
manner, some evaluation of mass balance can be done, but the applicant must have in mind, 
the limitation about the obtained values, since %area is a useful but not precise/accurate 
tool to determine concentrations. If during long-term stability studies or quality control 
determinations, the main active concentration decreases, mass balance investigations may 
start, evaluating %peak, DAD spectra and in parallel, different/contributing analytical 
techniques. 
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